NasdaqCM - Delayed Quote • USD
Jasper Therapeutics, Inc. (JSPR)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 8 |
| Avg. Estimate | -1.09 | -1.16 | -4.32 | -4.11 |
| Low Estimate | -1.31 | -1.34 | -4.82 | -5.08 |
| High Estimate | -0.96 | -0.98 | -3.82 | -2.44 |
| Year Ago EPS | -1.5 | -1.6 | -6.18 | -4.32 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 5 |
| Avg. Estimate | -- | -- | -- | 8.8M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 44M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.5 | -1.55 | -1.61 | -1.22 |
| EPS Actual | -1.5 | -1.6 | -1.5 | -1.03 |
| Difference | 0 | -0.05 | 0.11 | 0.19 |
| Surprise % | 0.00% | -3.20% | 6.80% | 15.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.09 | -1.16 | -4.32 | -4.11 |
| 7 Days Ago | -1.09 | -1.16 | -4.32 | -4.11 |
| 30 Days Ago | -1.19 | -1.22 | -4.96 | -4.32 |
| 60 Days Ago | -1.16 | -1.18 | -4.85 | -4.2 |
| 90 Days Ago | -1.15 | -1.16 | -5.19 | -2.83 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 4 | 3 | 5 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | JSPR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 27.30% | -- | -- | 9.10% |
| Next Qtr. | 27.50% | -- | -- | 11.50% |
| Current Year | 30.10% | -- | -- | 5.70% |
| Next Year | 4.90% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Initiated | HC Wainwright & Co.: Buy | 5/6/2024 |
| Initiated | Evercore ISI Group: Outperform | 4/3/2024 |
| Initiated | RBC Capital: Outperform | 3/28/2024 |
| Initiated | TD Cowen: Outperform | 3/18/2024 |
Related Tickers
PRAX Praxis Precision Medicines, Inc.
40.54
-7.51%
CLDX Celldex Therapeutics, Inc.
35.28
+0.48%
APGE Apogee Therapeutics, Inc.
41.69
-1.01%
AVTE Aerovate Therapeutics, Inc.
20.74
+4.17%
ZNTL Zentalis Pharmaceuticals, Inc.
10.62
-4.15%
ELEV Elevation Oncology, Inc.
3.5300
-4.08%
CRGX CARGO Therapeutics, Inc.
17.96
-0.17%
TARA Protara Therapeutics, Inc.
2.6700
-1.48%
REVB Revelation Biosciences, Inc.
2.2000
-3.08%
LPTX Leap Therapeutics, Inc.
2.2400
-0.44%